Corticosteroid Sparing Effects of Treatment With Guselkumab in Patients With Moderate to Severely Active Ulcerative Colitis: Phase 3 QUASAR Maintenance Study Results Through Week 44

被引：0

作者：

Bressler, Brian ^{[1
]}

Allegretti, Jessica R. ^{[2
]}

Rubin, David T. ^{[3
]}

Shipitofsky, Nicole ^{[4
]}

Huang, Kuan-Hsiang G. ^{[4
]}

Germinaro, Matthew ^{[4
]}

Wilson, Rebbecca ^{[5
]}

Zhang, Hongyan ^{[4
]}

Armuzzi, Alessandro ^{[6
]}

Fishman, Sigal ^{[7
]}

Wang, Yufang ^{[8
]}

Panes, Julian ^{[9
]}

Lichtenstein, Gary R. ^{[10
]}

Peyrin-Biroulet, Laurent ^{[11
,12
]}

机构：

[1] Univ British Columbia, IBD Ctr BC, Vancouver, BC, Canada

[2] Harvard Med Sch, Brigham & Womens Hosp, Boston, MA USA

[3] Univ Chicago Med, Inflammatory Bowel Dis Ctr, Chicago, IL USA

[4] Janssen Res & Dev, Spring House, PA USA

[5] Janssen Res & Dev LLC, Spring House, PA USA

[6] IRCCS Humanitas Res Hosp, Milan, Italy

[7] Sourasky Med Ctr, Tel Aviv, Israel

[8] Sichuan Univ, West China Hosp, Chengdu, Sichuan, Peoples R China

[9] Hosp Clin Barcelona, CIBERehd, IDIBAPS, Barcelona, Catalonia, Spain

[10] Univ Penn, Perelman Ctr Adv Med, Philadelphia, PA USA

[11] Nancy Univ Hosp, INFINY Inst, FHU CURE, INSERM NGERE, Vandoeuvre Les Nancy, Lorraine, France

[12] McGill Univ Hlth Ctr, Montreal, PQ, Canada

来源：

AMERICAN JOURNAL OF GASTROENTEROLOGY | 2024年 / 119卷 / 10S期

关键词：

D O I：

10.14309/01.ajg.0001034976.21441.52

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

S1402

引用

页码：S1002 / S1002

页数：1

共 50 条

[41] A PHASE 3 STUDY OF VEDOLIZUMAB FOR INDUCTION AND MAINTENANCE THERAPY IN JAPANESE PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
Watanabe, Mamoru
Motoya, Satoshi
Watanabe, Kenji
Ogata, Haruhiko
Kanai, Takanori
Matsui, Toshiyuki
Suzuki, Yasuo
Shikamura, Mitsuhiro
Igeta, Masataka
Oda, Kazunori
Hori, Tetsuharu
Araki, Takahiro
Hibi, Toshifumi
GASTROENTEROLOGY, 2018, 154 (06) : S380 - S381
[42] CORTICOSTEROID-FREE REMISSION IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS TREATED WITH OZANIMOD: RESULTS FROM THE MAINTENANCE PHASE OF TRUE NORTH
Schreiber, Stefan
Armuzzi, Alessandro
Dignass, Axel
Marta, Cecilia
Petersen, AnnKatrin
Huang, Vivian
Sandborn, William J.
GASTROENTEROLOGY, 2021, 160 (06) : S83 - S83
[43] Induction and Maintenance Treatment With Upadacitinib Improves Health-Related Quality of Life in Patients With Moderately to Severely Active Ulcerative Colitis: Phase 3 Study Results
Panes, Julian
Loftus, Edward, V
Higgins, Peter D. R.
Lindsay, James O.
Zhou, Wen
Yao, Xuan
Ilo, Dapo
Phillips, Charles
Tran, Jacinda
Sanchez Gonzalez, Yuri
Vermeire, Severine
INFLAMMATORY BOWEL DISEASES, 2023, : 1421 - 1430
[44] Maintenance of health-related quality of life improvements with upadacitinib treatment among patients with moderately to severely active ulcerative colitis: results from, 52-week phase, 3 study U ACHIEVE maintenance
Panes, J.
Loftus, E. V. J.
Higgins, P.
Lindsay, O.
Zhou, W.
Yao, X.
Ilo, D.
Phillips, C.
Tran, J.
Gonzalez, Y. Sanchez
Vermeire, S.
JOURNAL OF CROHNS & COLITIS, 2022, 16 : I373 - I374
[45] Maintenance of health-related quality of life improvements with upadacitinib treatment among patients with moderately to severely active ulcerative colitis: results from, 52-week phase, 3 study U ACHIEVE maintenance
Panes, J.
Loftus, E. V. J.
Higgins, P.
Lindsay, J. O.
Zhou, W.
Yao, X.
Ilo, D.
Phillips, C.
Tran, J.
Sanchez Gonzalez, Y.
Vermeire, S.
JOURNAL OF CROHNS & COLITIS, 2022, 16 : I373 - I374
[46] SUSTAINED REMISSION IN PATIENTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 UNIFI MAINTENANCE STUDY
Van Assche, Gert A.
Targan, Stephan R.
Baker, Thomas
O'Brien, Christopher D.
Zhang, Hongyan
Johanns, Jewel
Szapary, Philippe
Marano, Colleen W.
Leong, Rupert W.
Rowbotham, David
Hisamatsu, Tadakazu
Danese, Silvio
Sands, Bruce E.
Peyrin-Biroulet, Laurent
GASTROENTEROLOGY, 2019, 156 (06) : S1106 - S1107
[47] Sustained remission in patients with moderate to severe ulcerative colitis: Results from the Phase 3 UNIFI maintenance study
Van Assche, G.
Targan, S. R.
Baker, T.
O'Brien, C. D.
Zhang, H.
Johanns, J.
Szapary, P.
Marano, C.
Leong, R. W.
Rowbotham, D.
Hisamatsu, T.
Danese, S.
Sands, B. E.
Peyrin-Biroulet, L.
JOURNAL OF CROHNS & COLITIS, 2019, 13 : S54 - S55
[48] Corticosteroid-sparing effect of mirikizumab for the treatment of moderately-to-severely active Ulcerative Colitis: Extended induction subgroup analysis from Phase 3 trial
Laharie, D.
Siegel, C.
Dulai, P.
Matsuoka, K.
Gisbert, J.
Samaan, K.
Redondo, I.
Baygani, S.
Paulissen, J.
Jairath, V.
JOURNAL OF CROHNS & COLITIS, 2024, 18 : I1687 - I1688
[49] Efficacy and Safety of Upadacitinib Maintenance Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: Final Results From the Phase 3 U-ACHIEVE Maintenance Study
Vermeire, Severine
Danese, Silvio
Zhou, Wen
Yao, Xuan
Ilo, Dapo
Liu, John
Hebuterne, Xavier
Lindsay, James
Sanchez-Gonzalez, Yuri
Higgins, Peter D.
Colombel, Jean-Frederic
Panaccione, Remo
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2022, 117 (10): : S521 - S522
[50] EFFICACY AND SAFETY OF MIRIKIZUMAB AS MAINTENANCE THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 LUCENT-2 STUDY
Dubinsky, Marla C.
Irving, Peter M.
Li, Xingyuan
Howaldt, Stefanie
Pokrotnieks, Juris
Krueger, Kathryn A.
Laskowski, Janelle
Lissoos, Trevor
Milata, Joe
Morris, Nathan
Arora, Vipin
Milch, Catherine
Sands, Bruce E.
GASTROENTEROLOGY, 2022, 162 (07) : S1393 - S1394

← 1 2 3 4 5 →